Financial Review: Cue Biopharma (NASDAQ:CUE) & Entrada Therapeutics (NASDAQ:TRDA)

Cue Biopharma (NASDAQ:CUE) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk.

Analyst Recommendations

This is a summary of current ratings for Cue Biopharma and Entrada Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1	1	0	1	2.33
Entrada Therapeutics	1	2	4	0	2.43

Cue Biopharma currently has a consensus target price of $83.00, indicating a potential upside of 414.89%. Entrada Therapeutics has a consensus target price of $17.75, indicating a potential upside of 248.72%. Given Cue Biopharma’s higher possible upside, equities research analysts plainly believe Cue Biopharma is more favorable than Entrada Therapeutics.

Volatility and Risk

Cue Biopharma has a beta of 2.79, meaning that its stock price is 179% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500.

Profitability

This table compares Cue Biopharma and Entrada Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-435.83%	-620.06%	-291.15%
Entrada Therapeutics	-4,057.98%	-64.00%	-50.49%

Valuation and Earnings

This table compares Cue Biopharma and Entrada Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$37.66 million	3.11	-$26.60 million	($27.02)	-0.60
Entrada Therapeutics	$25.42 million	7.84	-$143.75 million	($3.84)	-1.33

Cue Biopharma has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Cue Biopharma beats Entrada Therapeutics on 8 of the 15 factors compared between the two stocks.

About Cue Biopharma

Cue Biopharma, Inc. is a biotechnology company developing biologic medicines designed to selectively engage and modulate T cells. Its Immuno-STAT platform is intended to direct immune activity toward disease-specific targets, with potential applications in cancer and autoimmune disorders. The company’s research has included cancer candidates such as CUE-101, designed to target HPV16-positive cancers, and CUE-102, developed to target cancers expressing the WT1 protein. Cue Biopharma has also pursued programs intended to influence immune responses in autoimmune disease.

About Entrada Therapeutics

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.